Rapport Therapeutics Overview
- Year Founded
-
2022
- Status
-
Public
- Employees
-
84
- Stock Symbol
-
RAPP
- Share Price
-
$23.16
- (As of Friday Closing)
Rapport Therapeutics General Information
Description
Rapport Therapeutics Inc is a clinical-stage biotechnology company dedicated to the discovery and development of small-molecule precision medicines for patients with neurological or psychiatric disorders. The company's portfolio of programs from its RAP technology platform includes RAP-219, an investigational small molecule being developed as a therapy for focal onset seizures, primary generalized tonic-clonic seizures, and bipolar mania. Additionally, it has two discovery-stage nicotinic acetylcholine receptor (nAChR) programs stemming from its RAP technology platform: one being developed for the treatment of chronic pain, and the second, being developed for the treatment of hearing disorders. Geographically, the company operates in the United States.
Contact Information
Website
www.rapportrx.comCorporate Office
- 99 High Street
- Suite 2100
- Boston, MA 02110
- United States
Corporate Office
- 99 High Street
- Suite 2100
- Boston, MA 02110
- United States
Rapport Therapeutics Timeline
Rapport Therapeutics Stock Performance
As of 20-Nov-2026, Rapport Therapeutics’s stock price is $23.16. Its current market cap is $1.37B with 59.3M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $23.16 | $23.58 | $22.06 - $52.93 | $1.37B | 59.3M | 781K | -$3.18 |
Rapport Therapeutics Financials Summary
As of 30-Sep-2026, Rapport Therapeutics has a trailing 12-month revenue of $20M.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 1,186,098 | 944,885 | 329,856 | |
| Revenue | 20,000 | 0 | 0 | 0 |
| EBITDA | (166,714) | (124,082) | (89,606) | (37,191) |
| Net Income | (150,470) | (111,483) | (78,307) | (34,786) |
| Total Assets | 418,558 | 512,431 | 314,933 | 155,423 |
| Total Debt | 9,391 | 11,484 | 1,476 | 2,146 |
Rapport Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Rapport Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
Rapport Therapeutics Comparisons
Industry
Financing
Details
Rapport Therapeutics Competitors (4)
One of Rapport Therapeutics’s 4 competitors is Sarepta Therapeutics, a Formerly VC-backed company based in Cambridge, MA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Sarepta Therapeutics | Formerly VC-backed | Cambridge, MA | ||||
| Contineum Therapeutics | Formerly VC-backed | San Diego, CA | ||||
| Coave Therapeutics | Venture Capital-Backed | Paris, France | ||||
| Ashvattha Therapeutics | Venture Capital-Backed | Redwood City, CA |
Rapport Therapeutics Patents
Rapport Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026165047-A1 | Nicotinic acetylcholine receptor modulators and uses therein | Pending | 29-Jan-2025 | ||
| WO-2025231416-A1 | Methods of use of ampa receptor modulators | Pending | 03-May-2024 | ||
| AU-2025209427-A1 | Crystalline forms of 3-(7-chloro-1h-indazol-5-yl)-2,5-bis(trifluoromethyl)-3h-imidazo[4,5-b]pyridine and their use in the treatment of epilepsy | Pending | 17-Jan-2024 | ||
| WO-2025155830-A1 | Crystalline forms of 3-(7-chloro-1h-indazol-5-yl)-2,5-bis(trifluoromethyl)-3h-imidazo[4,5-b]pyridine and their use in the treatment of epilepsy | Inactive | 17-Jan-2024 | ||
| US-10100045-B2 | 3-aryl-2h-pyrazolo[4,3-b]pyridine compounds and their use as ampa receptor modulators | Active | 26-Oct-2016 | C07D417/14 |
Rapport Therapeutics Signals
Rapport Therapeutics Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Rapport Therapeutics ESG
Risk Overview
Risk Rating
Updated November, 04, 2026
35.18 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,593
Rank
Percentile
Pharmaceuticals
Industry
of 852
Rank
Percentile
Biotechnology
Subindustry
of 431
Rank
Percentile
Rapport Therapeutics FAQs
-
When was Rapport Therapeutics founded?
Rapport Therapeutics was founded in 2022.
-
Where is Rapport Therapeutics headquartered?
Rapport Therapeutics is headquartered in Boston, MA.
-
What is the size of Rapport Therapeutics?
Rapport Therapeutics has 84 total employees.
-
What industry is Rapport Therapeutics in?
Rapport Therapeutics’s primary industry is Drug Discovery.
-
Is Rapport Therapeutics a private or public company?
Rapport Therapeutics is a Public company.
-
What is Rapport Therapeutics’s stock symbol?
The ticker symbol for Rapport Therapeutics is RAPP.
-
What is the current stock price of Rapport Therapeutics?
As of 20-Nov-2026 the stock price of Rapport Therapeutics is $23.16.
-
What is the current market cap of Rapport Therapeutics?
The current market capitalization of Rapport Therapeutics is $1.37B.
-
What is Rapport Therapeutics’s current revenue?
The trailing twelve month revenue for Rapport Therapeutics is $20M.
-
Who are Rapport Therapeutics’s competitors?
Sarepta Therapeutics, Contineum Therapeutics, Coave Therapeutics, and Ashvattha Therapeutics are competitors of Rapport Therapeutics.
-
What is Rapport Therapeutics’s annual earnings per share (EPS)?
Rapport Therapeutics’s EPS for 12 months was -$3.18.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process